Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2

Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2

Repurposing studies have identified several FDA-approved compounds as potential inhibitors of the intracellular domain of epidermal growth factor receptor 1 (EGFR) and human epidermal receptor 2 (HER2). EGFR and HER2 represent important targets for the design of new drugs against different types of...

Full description

Saved in:
Bibliographic Details
Main Authors: Irving Balbuena-Rebolledo (Author), Itzia Irene Padilla-Martínez (Author), Martha Cecilia Rosales-Hernández (Author), Martiniano Bello (Author)
Format: Book
Published: MDPI AG, 2021-08-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items